New (Post Pandemic 2009) UK Influenza Pandemic Preparedness StrategyArchived
Following an earlier consultation document issued in March 2011 the UK’s Secretary of State for Health, along with the UK’s developed administrations (N. Ireland, Scotland and Wales) published a new influenza pandemic strategy on 10 November.
Two evaluations of the response to the 2009 Pandemic in Spain: Surveillance and Vaccines and antiviralsArchived
Two official evaluations have been made by the national Ministry of Health of Spain of their country’s response to the 2009 influenza pandemic. The reviews focused on two particular topics - Surveillance and Vaccines and Antivirals.
Chronological overview of the 2009/2010 H1N1 influenza pandemic and the response of the Centre for Infectious Disease Control (RIVM)Archived
The Centre for Infectious Disease Control (CIb) of the Dutch National Institute for Public Health and the Environment (RIVM) has compiled a chronological overview of that country’s response to the 2009 influenza A(H1N1) pandemic.
Issues around the definitions and severity of pandemic influenzaArchived
This collection of article is intended to clarify the issues that arose, during the 2009 pandemic around definitions of the pandemic term, both in a theoretical and practical way.
Recommendation by the European Medicines Agency concerning Pandemrix vaccination and reports of narcolepsy in children and adolescentsArchived
EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.
EMA's Committee for Medicinal Products for Human Use (CHMP) issues opinion on narcolepsy and vaccination with Pandemrix®Archived
On 21 July 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued its opinion on the review of Pandemrix® and reports on narcolepsy. The CHMP recommended that in persons under 20 years of age Pandemrix® may only be used if the recommended seasonal trivalent influenza vaccine is not available and if immunisation against H1N1 is still needed (e.g. in persons at risk of the complications of infection).
Virological Risk Assessment of Pandemic Potential - EFSA Call for proposalsArchived
The European Food Standard Agency has recently published a call for proposals for a methodological framework for potentially pandemic influenza strains.
Poor pregnancy outcomes associated with maternal infection with the A(H1N1) 2009 virus during the pandemic – findings from a European cohort studyArchived
This large national cohort study followed-up pregnant women admitted to hospital and found to have laboratory-confirmed influenza A(H1N1) 2009 infection during the autumn-winter wave of the 2009 pandemic. The main objective was determining any adverse pregnancy outcomes attributable to the infection.
Case inventory study from Sweden concerning association of Pandemrix vaccination and reports of narcolepsy with cataplexy in children and adolescentsArchived
ECDC has previously summarised information concerning the appearance of narcolepsy following the use of a specific pandemic vaccine (Pandemrix®) in children and adolescents in three European Countries.